Summary: Using positron tomography and 76Br-labeled bromospiperone, a neuroleptic drug with high affinity for the dopamine (DA) receptors, we have estimated the spe cific binding of the radiotracer to striatal DA receptors in seven patients suffering from progressive supranuclear palsy. Compared with age-and sex-matched control sub jects, we found a significant (p < 0.02) decrease of the striatum-cerebellum uptake ratio in progressive supraRecent developments in positron emission to mography (PET) have shown that, using appro priate ligands, it is possible to investigate in vivo the distribution of specific binding sites in humans (Baron and Maziere, 1986; Phelps and Mazziotta, 1985) . The method has been applied to the musca rinic receptors in the myocardium (Syrota et aI., 1984(Syrota et aI., , 1985 and to the benzodiazepine (Samson et aI., 1985), the serotonin (Baron et aI., 1985a), the dopamine (DA) (Wagner et aI., 1983; Leenders et aI., 1984; Baron et aI., 1985b; Farde et aI., 1985; Maziere et aI., 1985), and the opiate (Frost et aI., 1985; Jones et aI., 1985) receptors in brain, and has consistently shown preferential accumulation of the labeled tracer in regions expected from in vitro binding assays to have the highest receptor density.
Recent developments in positron emission to mography (PET) have shown that, using appro priate ligands, it is possible to investigate in vivo the distribution of specific binding sites in humans (Baron and Maziere, 1986; Phelps and Mazziotta, 1985) . The method has been applied to the musca rinic receptors in the myocardium (Syrota et aI., 1984 (Syrota et aI., , 1985 and to the benzodiazepine (Samson et aI., 1985) , the serotonin (Baron et aI., 1985a) , the dopamine (DA) (Wagner et aI., 1983; Leenders et aI., 1984; Baron et aI., 1985b; Farde et aI., 1985; Maziere et aI., 1985) , and the opiate (Frost et aI., 1985; Jones et aI., 1985) receptors in brain, and has consistently shown preferential accumulation of the labeled tracer in regions expected from in vitro binding assays to have the highest receptor density.
A major advantage of PET over postmortem studies is that it may provide insight into receptor changes at various stages of the illness, as well as follow-up data on, and pharmacological modifica-nuclear palsy patients, suggesting loss of striatal DA re ceptors. This in vivo study confirms recent postmortem data on progressive supranuclear palsy patients and pro vides an explanation for the lack of benefit from L-DOPA and DA agonists in this condition, despite reduced ni grostriatal dopaminergic function. Key Words: 76Br_ Bromospiperone-Dopamine receptors-Positron to mography -Supranuclear palsy.
tion of, such changes. We chose to study the cen tral DA receptors in seven patients with progres sive supranuclear palsy (Steele, 1975) , an extrapy ramidal disorder where severe loss of striatal DA receptors, long suspected in view of the poor phar macological response to DA agonists, has recently been reported postmortem (Bokobza et aI., 1984) . A brief account of this work has appeared pre viously (Baron et aI., 1985 c) .
PATIENTS AND METHODS

Patients
We studied seven patients, three women and four men (mean age 66.4 ± 6 years), suspected on clinical grounds of supranuclear palsy ( Table 1) . They all complained of falls and were found to have intellectual disability sug gesting subcortical dementia. In addition, none of them responded favorably to DA agonists. Five patients were treated with L-DOPA and benserazide either singly (no. 7) or in association with bromocriptine (nos. 1, 2, 3, and 5), and one patient was treated with bromocriptine only (no. 6); these drugs were withdrawn 3-7 days before the PET study. Two patients (nos. 5 and 6) received medication for associated arterial hypertension and diabetes, but these drugs were not interrupted. The last patient (no. 4) had no treatment prior to PET study.
Our control series comprised 17 subjects (6 women and ized for various symptoms unrelated to the central nervous system (e.g., otitis media, arthritis, syncope, pe ripheral neuropathy etc.) and free from any history of in tellectual decline or brain disorder; none of them was on medication known to interfere with DA receptors. From this sample, seven subjects, matched for sex and age (mean 67.2 ± 7.5 years) to the progressive supranuclear palsy patients, were selected; four of them were treated for mild arterial hypertension.
Methods
We chose 76Br-labeled bromospiperone, a derivative of the potent neuroleptic spiperone, as the radioactive probe to study the central DA receptors (Maziere et aI., 1984 (Maziere et aI., , 1985 .
Preparation of [76Br]bromospiperone using cyclotron produced 76Br has been published elsewhere (Maziere et aI., 1984) . Pure, pyrogen-free, sterile [76Br ]bromo spiperone in acetate medium was injected intravenously as a slow bolus in a total dose of 1 mCi (range 0.8-1.2 mCi) with a specific radioactivity ranging from 0.5 to 2.0 Ci/f.lmol.
The studies were done on a time-of-flight positron camera (LETI prototype) that has three rings of CsF de tectors, allowing three direct slices and two cross-slices to be monitored simultaneously. Lateral resolution is -12 mm and slice thickness 13 mm using medium-resolution mode, with undetected space between slices of -3 mm (Soussaline et aI., 1984) . The subjects were carefully po sitioned in the head holder by means of crossed laser beams and using external bony landmarks placed ac cording to published PET atlases (Mazziotta et aI., 1981; Inoue et aI., 1985) so that the lowest slice included the cerebellar hemispheres [10 mm above and parallel to the orbitomeatal (OM) plane] and the third slice encom passed the striatum (40 mm above the OM plane). A 68Ge_68Ga transmission scan was collected before injec tion of radioligand for subsequent attenuation correction. All subjects were studied at rest, eyes closed and ears not plugged. Four hours and 30 min after injection, a 3D-min acquisition scan was obtained; at this time, as shown in long-term kinetic studies (Maziere et aI., 1985) , uptake of radioactivity in striatum has reached its highest value, while loss of count rate due to physical decay (tll2 of 76Br, 16.2 h) is still minimal. To tal image counts were typically -0.3 x 106 events. In addition, an early image (between 10 and 40 min after injection) was obtained in some studies. Accurate repositioning at late scan was ensured by using crossed laser beams projected on several ink marks drawn on the patient's face at the time of the early
scan. Whole-blood radioactivity concentration was mea sured on a venous sample at end scan time.
Data analysis
On the 4.5-h images, the striatum and the cerebellum were clearly visible in each case. To analyze the data as objectively as possible, two investigators independently used different methods, both being blind to the subject's condition (whether control or patient). One method used computer-controlled delineation of percentage isocon tour, yielding irregular regions of interest for cerebellum and for striatum. The other method used two circular re gions of interest covering the cerebellar hemispheres (area 12 cm2) that were positioned using a standard pro cedure (Pantano et aI., 1986) and two covering the striatal area (3 cm2). For each study, a mean (average of right and left values) striatal and a mean cerebellar value was ob tained, expressed in percentage of the injected dose per milliliter brain (corrected for 76Br decay); the value of the striatum-cerebellum ratio was then calculated.
Control data
Using this procedure, the striatum-cerebellum ratios found in 17 control subjects showed a highly significant linear decline with age that appeared roughly similar for men and women (Fig. 1) . (The tracer uptake in cere bellum at 5 min and at 4.5 h was independent of age, indi cating that ligand supply and nonspecific binding were age invariant and that the decline in the striatum-cere bellum ratio reflects a true decrease in specific binding.) A sample of seven sex-and age-matched control subjects was selected for comparison with the progressive supra nuclear palsy patients, using Student's t test.
RESULTS
In cerebellum, the mean tracer concentration at t = 4.5 h, expressed as a percentage of injected dose per liter brain, was 1.28 (± 0.32) and 1.47 (± 0.41) in controls and progressive supranuclear palsy pa tients, respectively (no significant difference). Likewise, the corresponding values in striatum were not significantly different in controls and palsy patients (2.27 ± 0.45 and 1.94 ± 0.61, re spectively).
In controls, the individual striatum-cerebellum radioactivity concentration ratios ranged from 1.45 
in a 79-year-old woman to 1.95 in a 59-year-old man, with a mean value of 1.74 (± 0.17). In pro gressive supranuclear palsy patients, it ranged from 0.90 to 1.57, with a mean of 1.32 (± 0.23). The dif ference between palsy patients and controls is highly significant (t = 3.955, dj = 12, p < 0.02) ( Table 2 ; Fig. 2 ).
DISCUSSION
The potent neuroleptic spiperone binds with high affinity to the D2 class of DA receptors, and is widely used for in vitro binding assays. After intra venous injection in trace amounts, labeled spip erone slowly accumulates in striatum of rats com pared with cerebellum (a reference organ that vir tually lacks DA receptors) as a result of specific binding in vivo (H611t et aI., 1977; Laduron et aI., 1978) Spiperone has been labeled for PET studies (Arnett et aI., 1983 (Arnett et aI., , 1985b Welch et aI., 1983) , but its radiochemical synthesis is difficult. Bromo spiperone and 3-methylspiperone retain the binding characteristics of spiperone (Huang et aI., 1980; Wagner et aI., 1983) , and have been shown to ac cumulate specifically in the striatum of baboons and humans in vivo (Wagner et aI., 1983; Welch et aI., 1983; Arnett et aI., 1984 Arnett et aI., , 1985a Leenders et a!., 1984; Maziere et a!., 1985) . We use 76Br-labeled bromos pi perone because of easy access to and ra diochemistry of 76Br, high specific radioactivity, and long physical half-life (16.2 h) allowing late imaging and hence more stable conditions. Exten sive studies in rats and baboons have demonstrated stereospecifically displaceable and saturable binding of bromos pi perone to striatal DA receptors in vivo; (Kulmala et a!., 1981; Owen et a!., 1983; Maziere et aI., 1984) . In control human subjects, [76Br]bromospiperone slowly accumulated in striatum, leading to a striatum-cerebellum concen tration ratio of 2.2 at 4.5 h after injection in young subjects (Maziere et a!., 1985) , a value that includes the partial volume effects (Mazziotta et aI., 1981) . In subjects loaded with cold neuroleptics, this ratio was reduced to 1.2, another argument indicating specific binding to striatal DA receptors in humans in vivo (Maziere et aI., 1985) . Bromospiperone thus appears a suitable ligand for human studies of DA receptors. The relatively small striatum-cere bellum ratio compared to e.g.
[llC]methylspiperone (Wong et aI., 1984) is largely compensated for by the small intersubject variability observed in con trols (Figs. 1; Ta ble 2). A major factor in the reli ability of the method is the very small amount of injected drug, theoretically resulting in 0.5-2% oc cupation of the DA receptors in human striatum Maziere et aI., 1985) . We found a significant decrease (p < 0.02) in the mean striatum-cerebellum ratio of progressive su pranuclear palsy patients as compared with con trols (Table 2) . Excluding the questionable value of 0.90 found in one patient does not alter the statis tical significance of the finding. Since there is no universally accepted method for obtaining wholly objective measures of zonal tracer concentration in PET images, we used two different methods inde pendently by "blind" investigators (see Methods): Interobserver concordance in the determination of the striatum-cerebellum ratio was excellent (r = 0.97, N = 28, p < 0.001), indicating that the data analysis is reliable and reproducible.
The physiological meaning of the striatum-cere bellum ratio has been investigated by compart mental modeling of the kinetics of labeled spip erone in brain in vivo (Mintun et aI., 1984) . This J Cereb Blood Flow Metab, Vol. 6, No.2, 1986 study suggests that the ratio depends essentially on the receptor-ligand interaction (i.e., affinity con stant and receptor density) and on nonspecific binding, and less so on a number of other param eters, among which are accessibility to the re ceptors (i.e., blood tracer concentration, blood flow, and penetration through the blood-brain bar rier) and competition with the endogenous (agonist) ligand. Kinetic modeling of the PET data can theo retically estimate each of these parameters, but the procedure is complex and not fully validated. On the other hand, the use of the striatum-cerebellum ratio as a reasonably accurate and easily measur able index of specific binding has been theoretically validated, provided it is measured at a postinjection interval long enough to reach essentially stable tracer concentration in brain and in blood (Wong et aI., 1984) . We chose the 4.5-h postinjection mea surement time as a reasonable trade-off between ideally stable conditions and acceptable tracer physical decay; at this time, tracer uptake in striatum has reached 94% of its plateau value, and tracer concentration in blood falls at a rate of only 5%/h (Maziere et al., 1985) . Our data indicate that nonspecific factors likely play no part in the de creased ratio found in progressive supranuclear palsy patients. Hence, the blood 76Br concentration at scanning time was identical in palsy patients and controls (0.49 ± 0. 16 and 0.48 ± 0,10% injected dose/L, respectively), and the early (t = 15 min) 76Br uptake in cerebellum was similar in palsy pa tients (N = 2) and controls (N = 4), suggesting equal accessibility of the ligand to the receptors. The fact that the tracer uptake at t = 4.5 h in cere bellum was similar in progressive supranuclear palsy and controls (see Results) indicates compa rable nonspecific binding. Also, DA levels should be markedly depressed in the striatum of progres sive supranuclear palsy patients (Bokobza et ai., 1984) , theoretically allowing increased, not de creased, bromospiperone binding (Friedman et ai., 1984) . Finally, the striatum-cerebellum ratio may be affected by labeled metabolites, but almost pure radio ligand was found in brain tissue sampled hours after intravenous injection of [18F]spiperone (Arnett et ai., 1985b) , and Crawley et al. (1983) indicated that [77Br]bromospiperone was excreted largely un changed in both urine and feces in normal volun teers. On the whole, the above considerations strongly suggest that the reduced striatum-cere bellum ratio truly reflects decreased specific binding compared with controls.
The significant age-related decline of the striatum-cerebellum ratio for both [IIC] methyl spiperone (Wong et aI., 1984) and [76Br]bromo spiperone ( Fig. 1) , expected from postmortem studies (Severson et al., 1982) , further confirms the reliability of this index as a measure of DA re ceptors in striatum in vivo. It also indicates that matching for age and perhaps also for sex (Wong et aI., 1984) is crucial when studying pathological cases. This condition was carefully met in the present study.
The interpretation of a decreased striatum-cere bellum ratio in progressive supranuclear palsy pa tients must consider the possible effects of ventric ular dilatation, which can reduce the measured ratio through partial voluming effects (Mazziotta et aI., 1981) . However, only two of our patients showed hydrocephalus on computed tomography (CT) scan (Table 1) , and their ratios were not dif ferent from those of the other patients (Table 2 ). In addition, two of the four controls who underwent CT scans also had mild hydrocephalus, indicating comparable bias in the two populations. Another potential complication arises from the anti parkin sonian drug regimen (see earlier): Despite drug in terruption for over 3 days and fast plasma clearance of L-DOPA and bromocriptine, a delayed effect of the measured binding capacity for bromospiperone in the striatum cannot be fully excluded. Hence, Schneider et aI., (1984) showed that both drugs re verse the hypersensitivity of striatal DA receptors after 6-0H-DA nigral lesion in rats; however, nei ther was able to reduce the receptor population to levels below those of control rats, suggesting that this treatment may not explain the actual decrease in bromospiperone binding found here. Finally, the only untreated patient (no. 4) had the lowest striatum-cerebellum ratio of the whole popUlation (Table 2) .
A decrease in the specific binding of bromo spiperone to striatal DA receptors can result from decreased affinity or decreased receptor density or both. Since affinity is rarely, if ever, affected by disease [as is true also of [3H]spiperone in progres sive supranuclear palsy brain postmortem (Bo kobza et ai., 1984)], decreased receptor density presumably explains our results. If the difference in [76Br]bromospiperone uptake between striatum and cerebellum is taken to represent specific binding (Laduron et al., 1978) , the age-adjusted loss of striatal receptor sites that can be calculated from our data (H. Cambon et al., unpublished observa tion) amounts to 60% (54% if patient no. 4 is ex cluded; range 38-76%), close to the figure of 45% found in the striatum of nine progressive supranu clear palsy patients postmortem (Ruberg et al., 1985) . Since bromospiperone has affinity for both the Dz dopaminergic and the 5-HTz serotonergic re ceptors (Maziere et ai., 1984) , these results may imply loss of Dz or 5-HT 2 sites or both. However, the fraction of ligand bound to 5-HT z receptors in striatum is probably <20% of total specific binding (Wagner et aI., 1983; Ruberg et ai., 1984) , indicating that the observed decrease in binding capacity es sentially represents loss of D2 receptor sites.
The physiological effects of the nigrostriatal DA pathway on striatal function are mediated through the Dz postsynaptic receptors (Stoof, 1983) . The latter being unaltered or increased in Parkinson's disease (Kato and Ban, 1982) , L-DOPA and DA agonists have beneficial as well as untoward effects in this condition. The nigrostriatal DA system is also severely damaged in progressive supranuclear palsy but the lack of response to L-DOPA has long suggested loss of D2 postsynaptic receptors in striatum despite minimal histological lesions (Steele, 1975) . Postmortem binding studies recently documented a mean decrease of 45% in striatal D2 receptor density in progressive supranuclear palsy (Ruberg et al., 1985) . The present study confirms these data, and extends them by showing this loss to occur during life not only in advanced, but also in early, stages of the disease. It also demonstrates that alterations in brain receptor density as a result of disease can be detected in vivo using PET.
